drugset / Trial / NCT04681248
Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors
Summary
An Expanded Access Protocol for use of DKN-01 for the treatment of advanced solid tumors.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DKN-01 | Monoclonal antibody | 600 mg | Intravenous |